A little more than a year ago, St. Jude Children’s Research Hospital announced the creation of its 2022–27 strategic plan. This bold commitment outlines a plan to accelerate progress in the laboratory, in the clinic and around the globe. Since then, we’ve been made gains across the plan’s five focus areas—fundamental science; childhood cancer; pediatric catastrophic diseases; global impact; and infrastructure, talent and culture. Based on what we’ve accomplished in the past year alone, the future is bright with possibilities.
Focus on Fundamental Science
Exploring an endless frontier of possibility

- The 625,000 square-foot Inspiration4 Advanced Research Center opened to provide laboratory, office and collaborative spaces for more than 1,000 scientists and administrative staff.
- Top investigator J. Paul Taylor, MD, PhD, was appointed scientific director to guide the institution’s basic science programs and related research efforts.
Focus on Childhood Cancer
Creating a brighter future for children today and generations to come

- The institution’s first dedicated clinical trials management system launched, uniting the St. Jude research community under one data platform to manage clinicals trials.
- The St. Jude HPV Cancer Prevention Program launched Path to a Bright Future, a national public awareness campaign to bring attention to the need for and benefits of receiving on-time human papillomavirus (HPV) vaccination to prevent cancer.
Focus on Childhood Catastrophic Diseases
Giving new hope to children with catastrophic diseases

- St. Jude opened a telehealth hematology clinic in Tupelo, Mississippi, to increase access to care for patients in that region. The move bridges care for scores of patients who live in an area with limited hematology services.
- The recently established Center for Experimental Neurotherapeutics enrolled its first patient in the DEVOTE clinical trial, the first interventional study for spinal muscular atrophy at St. Jude.
Focus on Global Impact
Moving science and medicine beyond borders and boundaries

- St. Jude Global announced a partnership with World Health Organization to create a first-of-its-kind platform that will provide pediatric cancer medicines at no cost to participating countries. The Global Platform for Access to Childhood Cancer Medicines represents a $200 million investment by St. Jude during the next five years.
- St. Jude Global supported children with cancer in Ukraine during the country’s invasion, leading evacuation efforts that helped more than 1,100 patients.
- The Global Pediatric Medicine Research Core strengthened infrastructure to launch international clinical trials.
Focus on a Culture of Excellence
Building a culture, workforce and environment that speeds cures for children

- Collective teams of scientists gathered on campus for the inaugural Joint Meeting of the St. Jude Research Collaboratives to share innovative ideas and connect with a cross-section of the institution’s researchers.
- Programs such as the High School and College Research Immersion Program and the Women in Leadership and Learning program launched to create a more inclusive career pipeline in the health and science fields.
- Construction on the Family Commons and The Domino’s Village moved forward.
Selected scientific and medical publications
Emerging from FY22-27 St. Jude Strategic Plan
-
St. Jude Children’s Research Hospital announces expansion of its strategic plan to target pediatric catastrophic diseases
07/13/2022
Six-year plan will now commit $12.9 billion to support 2,300 jobs, among other priorities.
-
STEMM immersion program to shape the next generation of scientists
07/11/2022
St. Jude High School and College Research Immersion Program introduces science to a diverse group of students
-
J. Paul Taylor, M.D., Ph.D., named scientific director and executive vice president of St. Jude
04/18/2022
Dr. Taylor steps into the role during a pivotal time of growth for St. Jude, as its scientific enterprise will significantly expand.
-
St. Jude Children’s Research Hospital evacuates second group of patients from Ukraine safely to United States
03/29/2022
Four more Ukrainian children with cancer and their 11 family members arrived at St. Jude Children’s Research Hospital in Memphis, Tennessee.
-
First Ukrainian pediatric cancer patients evacuated to U.S. arrive safely at St. Jude Children’s Research Hospital
03/22/2022
St. Jude continues to help move hundreds of Ukrainian children with cancer to safety so they can continue treatment.
-
St. Jude creates HPV cancer prevention awareness campaign to emphasize the need for HPV vaccination
03/04/2022
Emphasizing the need for HPV vaccination, the campaign launches March 4, 2022, International HPV Awareness Day.
-
St. Jude leases interim office space in Peabody Place as campus grows
02/16/2022
The hospital relocates 500 administrative employees to the temporary workspace during the construction phase of its six-year strategic plan.
-
World Health Organization and St. Jude Children’s Research Hospital to dramatically increase global access to childhood cancer medicines
12/13/2021
WHO and St. Jude will establish a platform to dramatically increase access to childhood cancer medicines in low- and middle-income countries
-
St. Jude researchers are again among the world’s most highly cited scientists
11/16/2021
The fourteen scientists are among the most highly cited investigators in the world during the past decade, reflecting the international reach of St. Jude research.
-
Powered by St. Jude, Together, a web-based patient education resource on childhood cancer, plans to launch in seven new languages
10/18/2021
Together by St. Jude announces plans to launch in seven new languages, offering trustworthy medical information about pediatric cancer and shared stories of hope to families around the world.
-
St. Jude acquires a facility dog for employee support
10/11/2021
Rosalie, a 60-pound golden retriever, joins St. Jude as a facility dog in the Staff Resilience Center dedicated to supporting employees.
-
St. Jude Children’s Research Hospital announces largest strategic expansion in its history targeting pediatric catastrophic diseases globally
04/27/2021
Six-year plan to invest $11.5 billion with donor support to accelerate research and treatment worldwide.